Published online March 1, 2006
PEDIATRICS Vol. 117 No. 3 March 2006, pp. 898-902 (doi:10.1542/peds.2005-1995)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Musculoskeletal System

SPECIAL ARTICLE

Screening for Developmental Dysplasia of the Hip: Recommendation Statement

US Preventive Services Task Force

Abbreviations: USPSTF—US Preventive Services Task Force • DDH—developmental dysplasia of the hip • AVN—avascular necrosis of the hip • AAP—American Academy of Pediatrics

The first 300 words of the full text of this article appear below.

The US Preventive Services Task Force (USPSTF) concludes that evidence is insufficient to recommend routine screening for developmental dysplasia of the hip (DDH) in infants as a means to prevent adverse outcomes (I recommendation).*

The pathophysiology and natural history of DDH are poorly understood. There is evidence that screening leads to earlier identification; however, 60% to 80% of the hips of newborns identified as abnormal or as suspicious for DDH by physical examination and >90% of those identified by ultrasound in the newborn period resolve spontaneously and require no intervention. There is poor evidence (poor-quality studies) of the effectiveness of both surgical and nonsurgical interventions; avascular necrosis of the hip (AVN) is reported in 0% to 60% of children who are treated for DDH. Thus, the USPSTF was unable to assess the balance of benefits and harms of screening for DDH but was concerned about the potential harms associated with treatment of infants identified by routine screening.


    CLINICAL CONSIDERATIONS
 

Address correspondence to Ned Calonge, MD, MPH, US Preventive Services Task Force, c/o Program Director, USPSTF, Agency for Healthcare Research and Quality, 540 Gaither Rd, Rockville, MD 20850. E-mail: uspstf@ahrq.gov




This article has been cited by other articles:


Home page
PediatricsHome page
V. A. Moyer and D. Nelson
Pediatricians and the US Preventive Services Task Force: A Natural Partnership to Enhance the Health of Children
Pediatrics, July 1, 2008; 122(1): 174 - 176.
[Full Text] [PDF]


Home page
JBJSHome page
D. J. Sucato and Y.-J. Kim
What's New in Pediatric Orthopaedics
J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1401 - 1411.
[Full Text] [PDF]


Home page
AAP NewsHome page
W. Hennrikus, R. Schwend, and J. Sarwark
Early detection of DDH can lead to simple, effective treatment
AAP News, September 1, 2007; 28(9): 10 - 10.
[Full Text] [PDF]


Home page
AAP Grand RoundsHome page
R. M. Schwend
A Reappraisal of the Ortolani Examination for Developmental Hip Dysplasia
AAP Grand Rounds, May 1, 2007; 17(5): 57 - 58.
[Full Text] [PDF]


Home page
PediatricsHome page
N. Calonge and D. Petitti
Screening for Developmental Dysplasia of the Hip: In Reply
Pediatrics, March 1, 2007; 119(3): 653 - 654.
[Full Text] [PDF]


Home page
PediatricsHome page
P. L. Schoenecker and J. M. Flynn
Screening for Developmental Dysplasia of the Hip
Pediatrics, March 1, 2007; 119(3): 652a - 653.
[Full Text] [PDF]


Home page
JWatch GeneralHome page
Screening for Developmental Dysplasia of the Hip
Journal Watch (General), March 21, 2006; 2006(321): 4 - 4.
[Full Text]